These cancer cells can avert TGFβ-induced cytostatic functions through the acquisition of activating mutations in oncogenes, for example, rat sarcoma (RAS) and MYC, and inactivating mutations in tumor suppressor genes, for example, p53 and retinoblastoma protein (Rb). This evidence concerns the gene TGFB1 and cancer.